Ann: Chairman's Address and CEO Presentation to 2018 AGM, page-51

From the CEO's AGM Presentation (page 6) - Delivery against 2018 Objectives:

_________

DX1 – TNBC brain metastases animal data

Q4 2018

DX1 – Additional solid cancer (TBC) animal data

Q1 2019

DX1 + radiation – brain cancer animal data

Q4 2018/Q1 2019

_________

From the CEO's AGM Presentation (Page 22) - Looking Ahead:

_________

DX1 + radiation – brain cancer animal data

Q4 2018/Q1 2019

DX1 – solid cancer (TBC) animal data

Q1 2019

DX1 + temazolamide – brain cancer animal data

Q1 2019

________

Comment: A couple of differences there. A far cry from the mid year and more straightforward

Aug 2018  - Solid cancer animal data

Oct 2018 - Additional solid cancer animal data

(neither of which materialised).

Also, wonder what happened to the provision of 'more complete pharmacokinetic profiling' (ann of 05-07-2018).

Sometimes silence is not golden. Easy to conclude things are not going exactly to plan.